The HIV vaccine pipeline, from preclinical to phase III

AIDS

Volumn 15, Issue SUPPL. 5, 2001, Pages

  Schultz, A M ^a   Bradac, J A ^a  

^a NONE   (United States)

Author keywords

AIDS vaccine; HIV; HIV protein immunogens; Nucleic acid immunization; Vaccine vectors

Indexed keywords

ALVAC B; ALVAC E; EPIMMUNE; EUROVAC; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NUCLEIC ACID; NYVAC; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ALPHA VIRUS; CANARYPOX VIRUS; CLINICAL TRIAL; DRUG RESEARCH; FLAVIVIRUS; FOWLPOX VIRUS; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; METHODOLOGY; MODIFIED VACCINIA VIRUS ANKARA; ORTHOMYXOVIRUS; PHASE 3 CLINICAL TRIAL; PICORNAVIRUS; PRIORITY JOURNAL; REPLICON; RETROVIRUS; REVIEW; RHABDOVIRUS; VACCINE PRODUCTION; VACCINIA VIRUS; VIRUS ATTENUATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 0035659831     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200100005-00018     Document Type: Review

References (86)

1. UN acknowledges HIV/AIDS as a threat to world peace
2. Live attenuated HIV vaccines: A proposal for further research and development
3. Advancing AIDSVAX to phase 3. Safety, immuno-genicity, and plans for phase 3
4. Induction of HIV-1-neutralizing and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
5. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1
6. HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells
7. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
8. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development
9. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: Effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
10. The antibody response in HIV-1 infection
11. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals
12. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques
13. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response
14. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
15. A novel vaccine regimen utilizing DNA, vaccinia virus and protein immunizations for HIV-1 envelope presentation
16. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
17. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
18. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
19. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution
20. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
21. Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins
22. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
23. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein
24. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades
25. DNA vaccination with the human immunodeficiency virus type 1 SF162deltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques
26. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
27. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
28. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
29. Covalently crosslinked complexes of human immuno-deficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates
30. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex
31. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype
32. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants
33. Applications of DNA shuffling to pharmaceuticals and vaccines
34. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques
35. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity
36. Multi-epitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine
37. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
38. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
39. Expression of AIDS virus envelope gene in recombinant vaccinia viruses
40. Vaccinia virus: A selectable eukaryotic cloning and expression vector
41. Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in macaques
42. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees
43. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
44. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism
45. Recombinant modified vaccinia virus Ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques
46. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV
47. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge
48. Applications of poxvirus vectors to vaccination: An update
49. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
50. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques
51. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
52. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein
53. Semliki Forest virus-based vaccines: Persistence, distribution and pathological analysis in two animal systems
54. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus
55. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia
56. Molecular genetic analysis of herpesviruses and their potential use as vectors for gene therapy applications
57. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
58. Neutralization of HIV type 1 infectivity by serum antibodies from a subset of autoimmune patients with mixed connective tissue disease
59. Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: High-level production of virus-like particles containing HIV envelope
60. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1
61. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates
62. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors
63. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases
64. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants
65. Development of novel influenza virus vaccines and vectors
66. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract
67. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus
68. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
69. Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120
70. Recent advances with recombinant bacterial vaccine vectors
71. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes
72. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera
73. Phage display of peptide epitopes from HIV-1 elicits strong cytolytic responses
74. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity
75. Codon usage limitation in the expression of HIV-1 envelope glycoprotein
76. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
77. Cationic microparticles: A potent delivery system for DNA vaccines
78. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection
79. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
80. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
81. HIV-1 vaccine-induced immune responses which correlate with protection from SHIV infection: Compiled preclinical efficacy data from trials with ten different HIV-1 vaccine candidates
82. Control of a mucosal challenge and prevention of AIDS in rhesus macaques by a multiprotein DNA/MVA vaccine
83. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya
84. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response
85. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys
86. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes